Muchiyedzo cheChikamu chechitatu, Dupixent yakawedzera kune yakajairwa-ye-kutarisira antihistamines yakapetwa kaviri kuderedzwa kweyakafunuka uye urticaria zviitiko zvichienzaniswa neyakajairwa-ye-kutarisira chete pamavhiki e3 mu biologic-naïve varwere vasingadzoreki pa antihistamines.
Dhata inosimbisa kugona kwekunongedza IL-4 uye IL-13, madhiraivha akakosha erudzi rwechipiri kuzvimba, mune iyi yakaoma chirwere chisingaperi.
Regeneron Pharmaceuticals, Inc. uye Sanofi nhasi vakazivisa mhedzisiro yakanaka yeDupixent® (dupilumab) muvarwere vane chisingaperi urticaria (CSU) avo vari biologic-naïve (kureva, vasina kumborapwa ne omalizumab). Muyedzo wakakosha wakaratidza kuwedzera Dupixent kune yakajairwa-ye-kutarisira antihistamines zvakanyanya kuderedza itch uye mikoko pamavhiki makumi maviri nemana zvichienzaniswa ne antihistamines chete mune ino yekuferefeta mamiriro. Mhedzisiro iyi ichaunzwa nhasi muchikamu chekupedzisira-chakatyora pa24 American Academy yeAllergy, Asthma uye Immunology (AAAAI) Musangano Wepagore.
"Pasinei neyakajairwa-ye-kutarisira antihistamines, varwere vazhinji vane chisingaperi urticaria isingaperi vanoramba vachinetsekana nekufunuka kwakanyanya, kupisa uye kurwadziwa kunoenderana nemikoko uye kuzvimba pasi peganda, izvo zvinogona kukanganisa zvakanyanya hupenyu hwavo hwezuva nezuva," akadaro Marcus Maurer, MD, Purofesa. yeDermatological Allergology, Kliniki yeDermatology, Venerology uye Allergology paCharité University of Medicine muBerlin, Germany. "Izvi zvinokurudzira zvakaratidza kuti, kune avo vasingakwanisi kuwana kudzora kwechirwere pa antihistamine chete, varwere vakawedzera dupilumab vakawana zviratidzo nezviratidzo zvakavandudzwa uye kudzora zviri nani chirwere chavo."
Topline mhinduro kubva ku randomized, double-blind, placebo-controlled controlled pivotal trial, iyo yakasangana nepuraimari uye zvose zvakakosha magumo ekupedzisira pavhiki 24, yakaziviswa muna Chikunguru 2021. Data yakaratidzwa pa 2022 AAAAI Annual Meeting yakaratidza kuti varwere vakawedzera Dupixent kune yakajairika. -ye-care antihistamines inenge yakapetwa kaviri kuderedzwa kweitch uye urticaria basa kana ichienzaniswa neyakajairwa-ye-kutarisira chete (placebo) nekuenderera mberi kwekuvandudza kusvika kumavhiki e24. Varwere ava vakasangana ne:
• 63% kudzikiswa kwehukuru hwekuvava neDupixent maringe ne35% ne placebo, sekuyerwa ne 0-21 point itch severity scale (10.24 point kudzikiswa neDupixent maringe ne 6.01 kudzikisira ne placebo, p<0.001), the primary endpoint muU. (yechipiri yekupedzisira muEU).
• 65% kuderedza mukuita urticaria (itch uye hive) kuoma neDupixent maringe ne37% ne placebo, sekuyerwa ne 0-42 point urticaria activity scale (20.53 point reduction neDupixent maringe ne12.00 point reduction ne placebo, p <0.001), iyo yekutanga yekupedzisira muEU (yechipiri yekupedzisira muUS).
Muyedzo wacho wakaratidza mhedzisiro yakafanana neyakavanzika chengetedzo mbiri yeDupixent mune yayo yakabvumidzwa dermatology zviratidzo. Kwenguva ye24-vhiki yekurapa, zviyero zvezviitiko zvakashata zvaiwanzofanana pakati peDupixent nemapoka e placebo (50% Dupixent, 59% placebo). Chiitiko chakanyanya kuipa chaive chiitiko chejekiseni saiti (11% Dupixent, 13% placebo).
Iko kushandiswa kweDupixent muCSU parizvino kuri pasi pekuvandudzwa kwekiriniki, uye kuchengetedzeka uye kushanda zvakanaka hakuna kuongororwa zvizere nechero chiremera chekutonga.
ZVOKUBVA MUNYAYA INO:
- Data presented at the 2022 AAAAI Annual Meeting showed that patients who added Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity compared to standard-of-care alone (placebo) with continuous improvement out to 24 weeks.
- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines.
- The pivotal trial showed adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks compared to antihistamines alone in this investigational setting.
